Drug
Efruxifermin
Efruxifermin: highest development phase Phase 3, developed by Akero Therapeutics. 4 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Akero Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| Efruxifermin NCT06161571 | Phase 3 | NASH/MASH |
| Efruxifermin NCT06215716 | Phase 3 | NASH With Fibrosis |
| Efruxifermin NCT06528314 | Phase 3 | NASH - Nonalcoholic Steatohepatitis |
| Efruxifermin NCT04767529 | Phase 2 | NASH - Nonalcoholic Steatohepatitis |
Latest
No recent events.
Follow Efruxifermin on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.